PMID- 36204893
OWN - NLM
STAT- MEDLINE
DCOM- 20221010
LR  - 20221011
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 18
IP  - 5
DP  - 2022 Sep
TI  - Bronchial artery chemoembolization with apatinib for treatment of central lung 
      squamous cell carcinoma.
PG  - 1432-1435
LID - 10.4103/jcrt.jcrt_2401_21 [doi]
AB  - OBJECTIVE: To evaluation the clinical efficacy and safety of bronchial artery 
      chemoembolization (BACE) combined with apatinib for treatment of advanced central 
      lung squamous cell carcinoma (LSCC). METHODS: Forty-seven patients with 
      pathologically diagnosed stage IIIB or IV central LSCC that was not resectable 
      were selected among hospital patients presenting after November 2016. Twenty-one 
      patients were treated with BACE combined with apatinib; the remaining patients 
      served as a control group treated with BACE alone. Objective response rate (ORR) 
      and disease control rate (DCR) were evaluated with postoperative 
      contrast-enhanced CT scans at 3, 6, and 12 months. Progression-free survival 
      (PFS) curves were used to evaluate curative effects. Adverse events were recorded 
      to assess safety. RESULTS: BACE operations were successfully completed in all 47 
      patients. Significant differences were found at six and 12 months (P < 0.05). 
      Median PFS was 322 days in the observation group and 209 days in the control 
      group: a statistically significant difference (P = 0.042). One-year survival 
      rates were 76.19% and 46.15% for observation and control patients, respectively; 
      this difference was also significant (P = 0.037). Three patients in the 
      observation group received emergency interventional embolization for hemoptysis, 
      and patients with grade III or greater adverse reaction events (AE) accounted for 
      19.05% of patients (4/21); these subjects improved or were controlled after 
      active treatment. CONCLUSION: BACE combined with apatinib is effective for 
      treatment of advanced central LSCC, with definite short-term efficacy, 
      controllable risk, and high safety. Investigation with a larger sample size is 
      warranted to confirm study results.
FAU - Zhu, Jun
AU  - Zhu J
AD  - Department of Intervention Radiology, The Second People's Hospital of Yibin, 
      Yibin, China.
FAU - Xu, Xiaoqian
AU  - Xu X
AD  - Out-Patient Department, The Centers for Disease Control and Prevention of Yibin, 
      Yibin, China.
FAU - Chen, Yaoyong
AU  - Chen Y
AD  - Department of Intervention Radiology, The Second People's Hospital of Yibin, 
      Yibin, China.
FAU - Wang, Qiang
AU  - Wang Q
AD  - Department of Intervention Radiology, The Second People's Hospital of Yibin, 
      Yibin, China.
FAU - Yue, Quanji
AU  - Yue Q
AD  - Department of Intervention Radiology, The Second People's Hospital of Yibin, 
      Yibin, China.
FAU - Lei, Kaijian
AU  - Lei K
AD  - Department of Oncology, The Second People's Hospital of Yibin, Yibin, China.
FAU - Jia, Yuming
AU  - Jia Y
AD  - Department of Oncology, The Second People's Hospital of Yibin, Yibin, China.
FAU - Xiao, Guo
AU  - Xiao G
AD  - Department of Intervention Radiology, The Second People's Hospital of Yibin, 
      Yibin, China.
FAU - Xu, Guohui
AU  - Xu G
AD  - Department of Intervention Radiology, Sichuan Provincial Cancer Hospital, Chendu, 
      Sichuan Province, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
SB  - IM
MH  - Bronchial Arteries/pathology
MH  - *Carcinoma, Non-Small-Cell Lung/pathology
MH  - *Carcinoma, Squamous Cell/drug therapy
MH  - Humans
MH  - Lung/pathology
MH  - *Lung Neoplasms/drug therapy
MH  - Pyridines
OTO - NOTNLM
OT  - Apatinib mesylate
OT  - bronchial artery chemoembolization
OT  - central lung squamous cell carcinoma
OT  - non-small-cell lung carcinoma
COIS- None
EDAT- 2022/10/08 06:00
MHDA- 2022/10/12 06:00
CRDT- 2022/10/07 03:03
PHST- 2022/10/07 03:03 [entrez]
PHST- 2022/10/08 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
AID - JCanResTher_2022_18_5_1432_357046 [pii]
AID - 10.4103/jcrt.jcrt_2401_21 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2022 Sep;18(5):1432-1435. doi: 10.4103/jcrt.jcrt_2401_21.